Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant

July 2011

Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant.

Viibryd (vilazodone) inhibits serotonin reuptake like SSRIs...plus it's also a partial serotonin agonist.

The company hoped Viibryd would be more effective than SSRIs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Dyslipidemia Lots of patients are asking if they should stop taking niacin (Niaspan, etc) for dyslipidemia
Diabetes confusing the news about Avandia and Actos
Diabetes how to manage diabetes during fasting
Corticosteroids The methylprednisolone shortage is forcing questions about alternative corticosteroids
Thyroid Disorders Many older adults get too much levothyroxine (Synthroid, etc)
Antidepressants Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant
Antidepressants Is it okay to combine an SSRI (fluoxetine, etc) with an SNRI (Effexor, Cymbalta, or Savella)
Respiratory & Allergy Singulair is "as good as" inhaled corticosteroids or long-acting beta-agonists for asthma
Respiratory & Allergy Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis
Infectious Diseases the new oral drug Dificid (fidaxomicin) for Clostridium difficile diarrhea
Restless Legs new option for restless legs syndrome, Horizant (hor-i-zant)
Statins stronger dosing limits for simvastatin